Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011;12(12):8562-74.
doi: 10.3390/ijms12128562. Epub 2011 Nov 29.

Insulin like growth factor-1 (IGF-1) causes overproduction of IL-8, an angiogenic cytokine and stimulates neovascularization in isoproterenol-induced myocardial infarction in rats

Affiliations

Insulin like growth factor-1 (IGF-1) causes overproduction of IL-8, an angiogenic cytokine and stimulates neovascularization in isoproterenol-induced myocardial infarction in rats

Nagaraja Haleagrahara et al. Int J Mol Sci. 2011.

Abstract

Angiogenesis factors are produced in response to hypoxic or ischemic insult at the site of pathology, which will cause neovascularization. Insulin like growth factor-1 (IGF-1) exerts potent proliferative, angiogenic and anti-apoptotic effects in target tissues. The present study was aimed to evaluate the effects of IGF-1 on circulating level of angiogenic cytokine interleukin-8 (IL-8), in experimentally-induced myocardial ischemia in rats. Male Sprague-Dawley rats were divided into control, IGF-1 treated (2 μg/kg/day subcutaneously, for 5 and 10 days), isoproterenol (ISO) treated (85 mg/kg, subcutaneously for two days) and ISO with IGF-1 treated (for 5 and 10 days). Heart weight, serum IGF-1, IL-8 and cardiac marker enzymes (CK-MB and LDH) were recorded after 5 and 10 days of treatment. Histopathological analyses of the myocardium were also done. There was a significant increase in serum cardiac markers with ISO treatment indicating myocardial infarction in rats. IGF-1 level increased significantly in ISO treated groups and the level of IGF-1 was significantly higher after 10 days of treatment. IL-8 level increased significantly after ISO treatment after 5 and 10 days and IGF-1 concurrent treatment to ISO rats had significantly increased IL-8 levels. Histopathologically, myocyte necrosis and nuclear pyknosis were reduced significantly in IGF-1 treated group and there were numerous areas of capillary sprouting suggestive of neovascularization in the myocardium. Thus, IGF-1 protects the ischemic myocardium with increased production of circulating angiogenic cytokine, IL-8 and increased angiogenesis.

Keywords: IGF-1; angiogenesis; interleukin-8; isoproterenol; myocardial ischemia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Photomicrographs of heart. (A) Normal heart from control group showing normal appearance of myocardial fibers in transverse section; (B) heart from IGF-10d group showing myocardium with adequate cellularity and normal morphology; (C) heart from ISO-5d showing a focally infarcted area surrounded by a zone of coagulative necrosis with numerous necrotic myocytes and scattered granulation tissue formation; (D) heart from ISO with IGF-1 for 10 days showing sprouting blood capillaries and extravasation of red blood cells between the myocardial muscle fibers.

Similar articles

Cited by

References

    1. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671–674. - PubMed
    1. Hudlicka O., Brown M., Egginton S. Angiogenesis in skeletal and cardiac muscle. Physiol. Rev. 1992;72:369–417. - PubMed
    1. Zielonka T.M., Demkow U., Filewska M., Bialas B., Korczynski P., Szopinski J. Angiogenic activity of sera from interstitial lung diseases patients in relation to IL-6, IL-8, IL-12 and TNF-α serum level. Centr. Eur. J. Immunol. 2007;32:53–60.
    1. Entman M.L., Michael L., Rossen R.D., Dreyer W.J., Anderson D.C., Taylor A.A. Inflammation in the course of early myocardial ischemia. FASEB J. 1991;5:2529–2537. - PubMed
    1. Kastrup J. Therapeutic angiogenesis in ischemic heart disease: gene or recombinant vascular growth factor protein therapy? Curr. Gene Ther. 2003;3:197–206. - PubMed

Publication types

MeSH terms